Deutsche Bank AG Buys Shares of 32,796 CONMED Corporation $CNMD

Key Points

• Deutsche Bank acquired 32,796 CONMED shares in the second quarter, worth approximately $1.07 million and representing 0.11% of the medical-device company.
• Analyst sentiment remains cautious: six analysts rate CONMED “Hold” and two rate it “Sell,” producing an average “Reduce” rating and a $41.40 target price, despite some recent target-price increases.
• CONMED exceeded quarterly expectations with EPS of $1.38 versus the $1.11 consensus and revenue of $343.49 million, while maintaining fiscal 2026 EPS guidance of $4.48–$4.60.

Deutsche Bank AG acquired a new stake in shares of CONMED Corporation (NYSE:CNMD - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 32,796 shares of the company's stock, valued at approximately $1,073,000. Deutsche Bank AG owned 0.11% of CONMED as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new stake in shares of CONMED during the fourth quarter worth about $26,000. Kelleher Financial Advisors bought a new stake in shares of CONMED in the third quarter valued at about $28,000. Aster Capital Management DIFC Ltd boosted its position in CONMED by 409.2% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 723 shares of the company's stock worth $29,000 after acquiring an additional 581 shares during the last quarter. Versant Capital Management Inc boosted its holdings in CONMED by 210.8% during the second quarter. Versant Capital Management Inc now owns 1,125 shares of the company's stock worth $37,000 after purchasing an additional 763 shares during the last quarter. Finally, Quarry LP grew its holdings in shares of CONMED by 244.8% in the 3rd quarter. Quarry LP now owns 869 shares of the company's stock valued at $41,000 after acquiring an additional 617 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on CNMD shares. Wells Fargo & Company boosted their target price on shares of CONMED from $39.00 to $46.00 and gave the stock an "equal weight" rating in a report on Thursday, July 30th. BMO Capital Markets assumed coverage on CONMED in a report on Wednesday, July 8th. They set a "market perform" rating and a $36.00 price target for the company. Piper Sandler reissued a "neutral" rating and issued a $45.00 price objective (up from $39.00) on shares of CONMED in a report on Thursday, July 30th. Wall Street Zen raised CONMED from a "hold" rating to a "buy" rating in a report on Monday, July 20th. Finally, Weiss Ratings raised shares of CONMED from a "sell (d)" rating to a "sell (d+)" rating in a research note on Wednesday, August 5th. Six investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Reduce" and an average target price of $41.40.

CONMED Price Performance

CNMD stock opened at $49.92 on Monday. The company has a market capitalization of $1.50 billion, a P/E ratio of 26.98, a PEG ratio of 2.28 and a beta of 0.88. CONMED Corporation has a 52-week low of $31.44 and a 52-week high of $56.63. The company has a fifty day moving average price of $43.47 and a 200-day moving average price of $39.81. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.69 and a current ratio of 1.48.

CONMED (NYSE:CNMD - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.11 by $0.27. The company had revenue of $343.49 million during the quarter, compared to the consensus estimate of $337.60 million. CONMED had a return on equity of 14.31% and a net margin of 4.12%.The firm's revenue was up .3% compared to the same quarter last year. During the same period last year, the company earned $1.15 earnings per share. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. As a group, equities analysts expect that CONMED Corporation will post 4.54 EPS for the current year.

CONMED Company Profile

CONMED Corporation NYSE: CNMD is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company's product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.

Want to see what other hedge funds are holding CNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CONMED Corporation (NYSE:CNMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source